• Vapotherm

  Led · Equity · Nov 2015

  Vapotherm develops and manufactures advanced, noninvasive respiratory care technologies, including its High Flow Therapy system. The company says its High Flow Therapy has treated over 700,000 patients. Vapotherm is based in Exeter, New Hampshire and is privately held. Management states the company focuses on improving clinical and economic outcomes for patients and customers. Vapotherm plans to expand its U.S. field organization, develop new products, and expand in select international markets. The recent financing is intended to fund those expansion and product development efforts. Vapotherm develops and manufactures advanced, noninvasive respiratory care technologies, including its High Flow Therapy system. The company is focused on improving clinical outcomes for patients with chronic and acute breathing disorders. Vapotherm is privately held and based in Exeter, New Hampshire. Management says the new capital will be used to continue building out a direct sales organization in the U.S. and to develop next-generation solutions. Over 700,000 patients have been treated with Vapotherm High Flow Therapy, indicating adoption at scale. The company closed a $20 million equity financing to support these growth plans. Vapotherm manufactures advanced, noninvasive respiratory care devices and high-flow therapy systems. The company is led by President & CEO Joe Army and focuses on respiratory support for patients with chronic or acute breathing disorders. Vapotherm has treated over 600,000 patients with its high flow therapy. It closed a $24M financing to support growth and improve healthcare for patients worldwide. In conjunction with the financing, a partner from the lead investor joined Vapotherm’s Board of Directors. The company intends to deploy the funds to expand and enhance its products and patient impact. Vapotherm manufactures advanced respiratory care devices and develops noninvasive technologies for supporting patients with chronic or acute breathing disorders. The company is led by founder Bill Niland and President & CEO Joe Army. It is based in Exeter, New Hampshire, and has an experienced board including James “Jim” Liken, a board member since April 2010 who will serve as Chairman. Vapotherm closed a $29M financing to support its operations. The company intends to use the proceeds from the financing to fund its growth plans. No operating metrics were disclosed in the article.

• Tryton Medical

  Led · Series D · Sep 2010

  Tryton Medical is the leading developer of stents designed to treat coronary bifurcation lesions. Its core product, the Tryton Side Branch Stent System, uses proprietary Tri‑ZONE® technology and a cobalt‑chromium design deployed in the side branch via a standard single‑wire balloon‑expandable delivery system while a conventional drug‑eluting stent is placed in the main vessel. The Tryton Side Branch Stent has been used to treat more than 10,000 patients worldwide, is commercially available in multiple countries across Europe, the Middle East & Africa, is investigational in the U.S., and is not available in Japan. Tryton is pursuing U.S. market clearance through the Pivotal IDE Trial and the Tryton IDE Extended Access Registry, with results from both intended for submission to the FDA. The company plans to develop the left main market opportunity based on a CE approved left main stent indication for its Tryton Side Branch Stent. Tryton completed an initial closing of a $20 million private equity financing to support registry enrollment, the FDA submission, and left main market development. Tryton Medical develops stent systems to treat coronary bifurcation lesions using its proprietary Tri-zone technology. Its cobalt chromium stent is deployed in the side branch with a standard single-wire balloon-expandable delivery system, after which a conventional drug-eluting stent is placed in the main vessel. The stent system has received CE Mark and is commercially available across Europe, Russia and the Middle East, while in the United States it is approved for investigational use only. The company, founded in 2003 and led by president and CEO Shawn P. McCarthy, intends to support a U.S. FDA submission this year and to expand its platform with a new stent system targeting left main disease. Tryton also plans to accelerate access into critical global markets, specifically in Asia. It recently held an initial closing of an aggregate $24M financing to support those plans. Tryton Medical, located in Durham, NC, develops novel stent systems for the treatment of coronary bifurcation lesions. Its Tryton Side Branch Stent System has CE Mark approval in Europe and has been implanted in more than 2,500 patients. The company was founded in 2003 by Aaron V. Kaplan, M.D., and Dan Cole. Tryton is privately held and venture-backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. Square 1 Bank has extended a $5 million term loan credit facility to the company. With the new facility, Tryton is enrolling in a pivotal U.S. clinical trial to advance its device toward broader market access. Tryton Medical develops the Tryton Side Branch Stent System, a dedicated strategy for treating atherosclerotic lesions in the side branch at coronary bifurcations. The system has shown excellent six-month clinical and angiographic results in a first-in-man study and similarly strong six-month clinical outcomes from nearly 200 patients across four registries, with a target lesion revascularization rate under 4%. The device has received CE Mark approval and is commercially available in 21 countries across Europe and the Middle East. It is not approved for use in the United States. The company plans to use new financing to conduct a U.S. pivotal trial and to drive broader international product adoption. Tryton is based in Durham, North Carolina.

• Accumetrics

  Participated · Equity · Sep 2010

  Accumetrics develops and markets the VerifyNow System, a point-of-care platform that measures platelet reactivity to major antiplatelet therapies including aspirin, P2Y12 inhibitors and GP IIb/IIIa inhibitors. The VerifyNow System is widely used in clinical settings where antiplatelet medications are prescribed to reduce future thrombotic events such as heart attack and stroke. The company reported an additional $7M raised in an ongoing financing round, bringing the round total to $24M. The capital infusion came primarily from existing investors. Accumetrics intends to use the funds to complete a number of key milestones and to continue expanding its global commercialization efforts. No operating metrics beyond the financing were disclosed in the article.

• Salient Surgical Technologies

  Participated · Series G · Jan 2010

  Salient Surgical Technologies develops and sells surgical devices that use transcollation to control bleeding during operations. The company began as TissueLink Medical and launched in August 1999 after securing an exclusive global license to Medtronic’s "wet" electrode technology. Its transcollation products seal soft tissue using radio-frequency energy and saline, closing vessels up to about 1 mm. The company reported estimated 2008 revenues of $45 million, a 55% increase that year. Salient has completed multiple financings—this is its seventh round over the past decade and its second since it shelved an $86 million IPO in late August 2008—and continues to receive venture and corporate backing. The company is based in Portsmouth, N.H., and Medtronic remains a long-time corporate patron, receiving licensing fees via promissory notes convertible into preferred stock.

No current team members are available.